Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 43, 2012, Pages 17615-17620

  Bernardo, Bianca C ^a   Gao, Xiao Ming ^a   Winbanks, Catherine E ^a   Boey, Esther J H ^a   Tham, Yow Keat ^a   Kiriazis, Helen ^a   Gregorevic, Paul ^a   Obad, Susanna ^b   Kauppinen, Sakari ^b,c   Du, Xiao Jun ^a   Lin, Ruby C Y ^d   McMullen, Julie R ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b Santaris Pharma AS   (Denmark)

^c AALBORG UNIVERSITY   (Denmark)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cardiomyocyte; Heart failure; Pathological hypertrophy; Physiological hypertrophy; PI3K

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ATRIAL NATRIURETIC FACTOR; LOCKED NUCLEIC ACID MODIFIED ANTIMIR 34; MICRORNA; MICRORNA 26A; MICRORNA 34A; MICRORNA 34B; MICRORNA 34C; NOTCH1 RECEPTOR; PROTEIN KINASE B; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SEMAPHORIN; SEMAPHORIN 4B; UNCLASSIFIED DRUG; VASCULOTROPIN; VINCULIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; GENE SILENCING; HEART ATRIUM ENLARGEMENT; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART STRESS; HEART VENTRICLE REMODELING; LUNG CONGESTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BASE SEQUENCE; DNA; DNA-BINDING PROTEINS; FUCOSYLTRANSFERASES; HEART FUNCTION TESTS; MICE; MICRORNAS; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES; SEMAPHORINS; UP-REGULATION; VENTRICULAR REMODELING; VINCULIN;

EID: 84867903854     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1206432109     Document Type: Article

References (40)

1. Cubbon RM, et al. (2011) Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: A study across therapeutic eras. Circ Heart Fail 4(4):396-403.
2. McMurray JJ (2010) Clinical practice: Systolic heart failure. N Engl J Med 362(3):228-238.
3. van Rooij E, Purcell AL, Levin AA (2012) Developing microRNA therapeutics. Circ Res 110(3):496-507.
4. Small EM, Olson EN (2011) Pervasive roles of microRNAs in cardiovascular biology. Nature 469(7330):336-342.
5. Bernardo BC, Charchar FJ, Lin RC, McMullen JR (2012) A microRNA guide for clinicians and basic scientists: Background and experimental techniques. Heart Lung Circ 21(3):131-142.
6. Elmén J, et al. (2008) Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver. Nucleic Acids Res 36(4):1153-1162. (Pubitemid 351330933)
7. Elmén J, et al. (2008) LNA-mediated microRNA silencing in non-human primates. Nature 452(7189):896-899. (Pubitemid 351550859)
8. Stenvang J, Petri A, Lindow M, Obad S, Kauppinen S (2012) Inhibition of microRNA function by antimiR oligonucleotides. Silence 3(1):1.
9. McMullen JR, et al. (2003) Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 100(21):12355-12360. (Pubitemid 37271564)
10. McMullen JR, et al. (2004) The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J Biol Chem 279(6):4782-4793. (Pubitemid 38199073)
11. Bernardo BC, Weeks KL, Pretorius L, McMullen JR (2010) Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacol Ther 128(1):191-227.
12. Weeks KL, et al. (2012) Phosphoinositide 3-kinase p110α is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ Heart Fail 5(4):523-534.
13. Lin RC, et al. (2010) PI3K(p110 alpha) protects against myocardial infarction-induced heart failure: Identification of PI3K-regulated miRNA and mRNA. Arterioscler Thromb Vasc Biol 30(4):724-732.
14. McMullen JR, et al. (2007) Protective effects of exercise and phosphoinositide 3-kinase (p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 104(2):612-617. (Pubitemid 46123073)
15. Pretorius L, et al. (2009) Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am J Pathol 175(3):998-1009.
16. Thum T, et al. (2007) MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation 116(3):258-267. (Pubitemid 47196561)
17. Greco S, et al. (2012) MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes 61(6):1633-1641.
18. Krützfeldt J, et al. (2005) Silencing of microRNAs in vivo with "antagomirs." Nature 438(7068):685-689.
19. Davis S, et al. (2009) Potent inhibition of microRNA in vivo without degradation. Nucleic Acids Res 37(1):70-77.
20. Obad S, et al. (2011) Silencing of microRNA families by seed-targeting tiny LNAs. Nat Genet 43(4):371-378.
21. Tamamori-Adachi M, et al. (2008) Cardiomyocyte proliferation and protection against post-myocardial infarction heart failure by cyclin D1 and Skp2 ubiquitin ligase. Cardiovasc Res 80(2):181-190.
22. Hsu CP, et al. (2010) Silent information regulator 1 protects the heart from ischemia/reperfusion. Circulation 122(21):2170-2182.
23. Boon RA, et al. (2010) Inhibition of the age-induced microRNA-34 improves recovery after AMI in mice. Circulation 122(21):A14023.
24. Zemljic-Harpf AE, et al. (2007) Cardiac myocyte-specific excision of the vinculin gene disrupts cellular junctions, causing sudden death or dilated cardiomyopathy. Mol Cell Biol 27(21):7522-7537. (Pubitemid 350033658)
25. Li Y, Hiroi Y, Liao JK (2010) Notch signaling as an important mediator of cardiac repair and regeneration after myocardial infarction. Trends Cardiovasc Med 20(7):228-231.
26. Okamura Y, Saga Y (2008) Pofut1 is required for the proper localization of the Notch receptor during mouse development. Mech Dev 125(8):663-673.
27. Yoshida T, et al. (1999) The role of Bcl6 in mature cardiac myocytes. Cardiovasc Res 42(3):670-679. (Pubitemid 29298136)
28. Lähteenvuo JE, et al. (2009) Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. Circulation 119(6):845-856.
29. Shiojima I, et al. (2005) Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115(8):2108-2118. (Pubitemid 41134152)
30. Nalls D, Tang SN, Rodova M, Srivastava RK, Shankar S (2011) Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS ONE 6(8):e24099.
31. Ye W, et al. (2008) The effect of central loops in miRNA:MRE duplexes on the efficiency of miRNA-mediated gene regulation. PLoS ONE 3(3):e1719.
32. Wei J, et al. (2012) miR-34s inhibit osteoblast proliferation and differentiation in the mouse by targeting SATB2. J Cell Biol 197(4):509-521.
33. Porrello ER, et al. (2011) MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes. Circ Res 109(6):670-679.
34. Montgomery RL, et al. (2011) Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 124(14):1537-1547.
35. Hullinger TG, et al. (2012) Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res 110(1):71-81.
36. Nakagawa Y, et al. (2011) Identification of semaphorin 4B as a negative regulator of basophil-mediated immune responses. J Immunol 186(5):2881-2888.
37. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408(6810):307-310.
38. Bader AG, Brown D, Winkler M (2010) The promise of microRNA replacement therapy. Cancer Res 70(18):7027-7030.
39. Concepcion CP, et al. (2012) Intact p53-dependent responses in miR-34-deficient mice. PLoS Genet 8(7):e1002797.
40. Silber J, et al. (2012) miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS ONE 7(3):e33844.